Sentences with phrase «with a donation based»

PRIMAVERA, a pioneering, German - based line of natural and organic skincare and aromatherapy, will commemorate Breast Cancer Awareness Month with a donation based on product sales to the organization Look Good... Feel Better.

The museum is a private non-profit with a donation based admission program.

Not exact matches

The fit seems natural for Jet, considering their own dabbling with value - based innovation in a natural, eco-friendly cleaning line and the opportunity to tack on charitable donation at checkout.

But the current generation of donation - based crowdfunding platforms doesn't mesh particularly well with the franchise model.

While Asia has a handful of donation - based crowdfunding platforms which don't need any regulations, it still needs to catch up with its neighbors in terms of equity crowdfunding regulations.

KICKICO is an online blockchain technology - based platform for reward - based and donation - based crowdfunding, which provides an access to online fundraising tools carried out with the help of blockchain technology and smart contracts.

Donation - based crowdfunding is popular with charities.

BC is one of few provinces with no limit on corporate donations (as is Saskatchewan, whose leading political party appears to have benefitted handsomely from vast sums of money from Alberta - based fossil fuel corporations over the last decade).

I agree with the concept but your numbert are high, The worst I found was the American Tract Society (based in Texas, distributes religious literature to spread its message around the world) which used 68 % of donations for their Administrative expenses.

That's why you find many churches helping the poor DIRECTLY with food, clothing, gas money, community - based programs, donations of money and labor to people affected by natural disasters, etc..

As part of our ongoing system of monitoring, restaurants with an active agency that have not reported donations on a regular basis are also contacted to determine if an issue needs resolved or simply remind the restaurant or agency to send in information on donations.

In collaboration with food donation organizations, NGOs, waste experts, and a host of other partners along the supply chain, FWRA produces workable resources, such as best practices in reducing food waste, that offer reality - based applications and guidance to the various aspects of our food production system.

As the presenting sponsor of the 14th Annual Waikiki SPAM JAM ® Festival, Outrigger Resorts and OHANA Hotels in Waikiki will be offering guests checking in for the weekend a free one - category upgrade, based on availability, with the donation of a can of SPAM ® product, which is then donated to the Hawaii Foodbank.

Ultimately, we find that egg donors will often agree to be known or anonymous based on the preference of the intended parents, but the majority of donors who come to Circle Surrogacy are comfortable with a known egg donation.

According to the Birmingham, Ala. - based Society for Assisted Reproduction Technology, 547 egg donations were done in 1990, compared with 60 in 1987.

In addition to helping individual families and non-profits on a monthly basis, 4moms Cares supports organizations like Operation Shower, The Good + Foundation and Project Sweet Peas with larger product donations.

Funding based on votes at the last election with a small cap for matched donations (# 10,000?).

It's particularly tough for candidates with a progressive ethos like Democrat Cynthia Nixon who has vowed to take no corporate money while relying on smaller donations to at least project the image of a campaign based entirely on grassroots support.

Just as political organizers and fundraisers have tried to make the most of emotional moments with mobile technology by devising mobile donation systems that can enable giving at rallies and political events, Garvin thinks that canvas managers can update surveys based on news events and inopportune comments by politicians on the other side of an issue.

Filings with the Federal Elections Commission show that Democrat Zephyr Teachout has outraised Republican John Faso in the race for the 19th Congressional District by relying largely on small donations from her activist base.

The state Education Department is developing the lessons now with the New York Alliance for Donation based on a bill sponsored by Ortiz and Senate Majority Leader John Flanagan (R - East Northport).

Haven, with NYPIRG, believes, based on his study of the new law that set up the ethics commission, that the public likely won't see details of any donations to the Committee to Save New York from 2011.

The donations began around the time some two years ago when the Rochester - based Wilmorite, a development corporation, filed a request for a payment - in - lieu - of - taxes (Pilot) agreement with the county's Industrial Development Agency.

Revelations that Ulster County Executive Mike Hein received $ 11,500 in campaign donations over the last two years from the developers of the proposed Park Point student housing project in New Paltz, with an additional $ 5,000 in contributions from their Albany - based, county - connected law firm, have further roiled the muddy waters gurgling around this controversial project.

I read with some interest published reports on County Executive Mike Hein explaining his acceptance of $ 11,500 in campaign donations from a Rochester - based developer seeking to build a $ 56 million student and faculty housing project in New Paltz.

Many of Teachout's donations came from outside of the district and outside New York based on her high profile among the progressive left, Faso said, rather than any real connection with Hudson Valley residents.

A de Blasio spokesman denied any connection between WeWork's donations and lobbying, and the work done at the Wall Street building, saying: «It was approved based on its merits and its compliance with existing building codes and the city's zoning resolution, as is the case for all building projects under this administration.»

Importantly though, the donation rates in these areas were lower than adjacent metropolitan areas with similar demographics, highlighting that variable donation rates at a macro-level is based on variable OPO performance and community - level engagement in donation, and not the underlying demographics of the population, which is often what many OPOs cite as the cause of lower donation numbers.

The research team identified potential deceased donors based on specific criteria such as a ventilated inpatient death of a patient 75 years or younger, without multi-organ system failure, sepsis, or cancer, and whose cause of death was consistent with organ donation — which includes neurologic determination of death (DNDD) or circulatory determination of death (DCDD).

Results showed that the egg donation patients had a more than three-fold higher risk of pregnancy - induced hypertension than the routine IVF patients, with prevalence rising from 5.3 % to 17.8 % (odds ratio 3.84, 95 % CI 1.89 - 7.77) and an even higher risk of pre-eclampsia, from 2.8 % to 11.2 % (OR 4.60, 95 % CI 1.81 - 11.67)-- although the latter finding was based on very few numbers.

He had only recently met the wealthy, Cambridge, Massachusetts - based software executive and was about to spend two full days touring AIDS - ravaged Durban with him in hope of obtaining a donation.

As such the Centre seeks donations from a wide variety of organisations with an interest in the accurate reporting of science in the mass media, including scientific institutions, science - based companies, charities, media organisations and government.

Cymerus is a patented stem cell manufacturing process that avoids the problems often associated with deriving MSCs and primary tissue sources, and has the potential to generate large - scale, low - cost MSCs based on a single blood donation from one adult donor.

Table 1: Selection, Design & Construction of HSV - based Oncolytic Viruses Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & AcquisiBased on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisitions

Amandine's classes are donation based, with half of the proceeds going to charity and the other half going to supplies.

The full evolution of the Inner Fire model, however, aims to fund all operations from a robust endowment, allowing program participation based solely on need, with donations by participants encouraged to advance and spread the development of this treatment option to other locations in the United States and beyond.

Join us for a donation - based class with Exhale to Inhale Founder Zoë LePage.

Training Ground TransformationNATION has made a commitment to match any donations given for this one day event, which involved an hour - long, intense circuit - style workout with weights, bodyweight exercises and a variety of athletic training equipment at their Palos Hills - based facility off of 17th St. and Pomona Ave.

There are opportunities for you to practice with Ahlia privately, semi-privately, in studio, and her outdoor donation based classes (see the Sunshine Yoga Group on Facebook for updates and locations.

This activity is entirely run by volunteers on a donation - basis, and they provide you with the life jacket and kayak for 20 minutes.

Donations to the program are offset with a dollar - for - dollar tax credit, up to $ 1,000 for individuals, $ 2,500 for families, and $ 10,000 for businesses.14 Tax - credit - eligible donations are capped at $ 58 million annually and are available on a first - come, first - servDonations to the program are offset with a dollar - for - dollar tax credit, up to $ 1,000 for individuals, $ 2,500 for families, and $ 10,000 for businesses.14 Tax - credit - eligible donations are capped at $ 58 million annually and are available on a first - come, first - servdonations are capped at $ 58 million annually and are available on a first - come, first - served basis.

According to their research, districts that were already advantaged — with larger tax bases and more educated parent populations — received more money in private donations.29

Ms. Grimm, whose family fortune was made in agriculture, stepped up her donations after her blended learning (computer - based instruction) charter, with its «edible education program,» won an award from CCSA.

Since 2015, The Mind Trust has raised $ 31 million, with sizable donations from national entities, including the Arkansas - based Walton Family Foundation and Austin, Texas - based Michael and Susan Dell Foundation.

With that in mind, we have posted a table below based on the levels of donations families have made in the past, as a suggestion in case your family is considering donating more than the per capita level.

The two somewhat similar companies, PubSlush and LeanPub, began offering a platform solely based on the idea that authors could reach out to potential readers while the book is still in the process of being written and accept funding to help cover the costs associated with publishing the book; around this same time, Wattpad rolled out a limited pilot program that worked with six authors to fund their titles through reader donations.

New Orleans - based nonprofit SBP is also seeking donations to rebuild homes damaged or destroyed by the storm with help from AmeriCorps volunteers and staff.

This week, Krause expanded her range of analysis with a report on a Vancouver - based network of charitable foundations that, in recent years, processed more than $ 575 million in revenues and donations through a complex web of dozens of foundations.

«Based on the source of donations, these seem more like investments with expected returns rather than donations from party faithful.»

For each delegate who registers for the Hill's Global Symposium, either live in Lisbon or via the 24 - hour livestream, Hill's will make a $ 1 donation to Dogs for Good, a U.K. - based charity that trains and provides accredited assistance dogs to people with physical disabilities, elderly people and children with autism (up to a total amount of $ 10,000).